Lombard Odier reports 4.2% Silence Therapeutics (SLN) stake

Rhea-AI Filing Summary

Lombard Odier Asset Management (USA) Corp reports beneficial ownership of 5,935,955 ordinary shares of Silence Therapeutics plc, representing 4.2% of the company. This holding includes 1,978,650 American Depositary Shares, each representing three ordinary shares.

The ownership percentage is calculated using 141,701,848 ordinary shares issued and outstanding as of October 30, 2025. All voting and dispositive power over these shares is shared, with no sole voting or dispositive authority reported.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

Silence Therapeutics plc

(Name of Issuer)

Ordinary Shares, par value GBP 0.05 per share (the "Shares")

(Title of Class of Securities)

G8128Y157

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G8128Y157

1

Names of Reporting Persons

Lombard Odier Asset Management (USA) Corp

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,935,955.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,935,955.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,935,955.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Silence Therapeutics plc
(b)	Address of issuer's principal executive offices: 12 Hammersmith Grove, London, United Kingdom, W6 7AP
Item 2.
(a)	Name of person filing: This statement is filed by Lombard Odier Asset Management (USA) Corp (the "Investment Advisor"), with respect to ADSs (as defined in Item 4) held by 1798 Volantis Fund Ltd, 1798 UK Small Cap Best Ideas Fund Ltd and one or more managed accounts. The Investment Advisor serves as the investment advisor to each of the foregoing.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of the Investment Advisor is 452 Fifth Avenue, 25th Floor, New York, NY 10018.
(c)	Citizenship: The Investment Advisor is a corporation organized under the laws of the State of Delaware.
(d)	Title of class of securities: Ordinary Shares, par value GBP 0.05 per share (the "Shares")
(e)	CUSIP No.: G8128Y157
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of the date requiring the filing of this statement, the Investment Advisor beneficially owns an aggregate of 5,935,955 Shares, inclusive of 1,978,650 American Depositary Shares ("ADSs"), each of which represents, and at the holder's option is convertible into, three Shares. The percentages used herein and in the rest of this Schedule 13G are calculated based upon 141,701,848 Shares issued and outstanding as of October 30, 2025, as reported by the Company in its Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025.
(b)	Percent of class: 4.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 5,935,955
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 5,935,955
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lombard Odier Asset Management (USA) Corp

Signature:	/s/ Elyse Strauss
Name/Title:	Authorized Signatory
Date:	02/09/2026

FAQ

What percentage of Silence Therapeutics (SLN) does Lombard Odier Asset Management own?

Lombard Odier Asset Management (USA) Corp beneficially owns 4.2% of Silence Therapeutics plc. This corresponds to 5,935,955 ordinary shares, with the percentage calculated using 141,701,848 ordinary shares outstanding as of October 30, 2025, as reported by the company.

How many Silence Therapeutics shares are reported as beneficially owned in this Schedule 13G/A?

The filing reports beneficial ownership of 5,935,955 ordinary shares of Silence Therapeutics plc. This total includes holdings through American Depositary Shares and reflects the aggregate position across funds and managed accounts advised by Lombard Odier Asset Management (USA) Corp.

How are American Depositary Shares (ADSs) for Silence Therapeutics structured in this filing?

The filing states that 1,978,650 American Depositary Shares are included in the position. Each ADS represents, and at the holder’s option is convertible into, three ordinary shares, so these ADSs form a significant part of the total reported beneficial ownership.

What is the share count used to calculate Lombard Odier’s 4.2% stake in Silence Therapeutics (SLN)?

The 4.2% ownership figure is based on 141,701,848 ordinary shares issued and outstanding. This share count is cited as of October 30, 2025, and was reported by Silence Therapeutics in a Form 10-Q filed with the Securities and Exchange Commission.

Does Lombard Odier have sole or shared voting power over Silence Therapeutics shares?

Lombard Odier Asset Management (USA) Corp reports no sole voting power and shared voting power over 5,935,955 shares. It also reports no sole dispositive power, with shared dispositive power over the same number of shares, reflecting its role as investment adviser for multiple clients.

What type of reporting person is Lombard Odier Asset Management in this Silence Therapeutics filing?

Lombard Odier Asset Management (USA) Corp is classified as an investment adviser. The firm files on behalf of funds and managed accounts holding Silence Therapeutics securities, reflecting its role under the investment adviser category specified in the beneficial ownership reporting rules.